

# Nadia Solowij

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4895911/publications.pdf>

Version: 2024-02-01

112  
papers

8,788  
citations

66315

42  
h-index

45285

90  
g-index

120  
all docs

120  
docs citations

120  
times ranked

8159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute effects of $\delta^9$ -tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. <i>Psychopharmacology</i> , 2022, 239, 1409-1424.	1.5	2
2	Brain structural covariance network differences in adults with alcohol dependence and heavy-drinking adolescents. <i>Addiction</i> , 2022, 117, 1312-1325.	1.7	4
3	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 719-742.	1.3	40
4	Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity. <i>GeroScience</i> , 2022, 44, 1505-1524.	2.1	16
5	Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 627-635.	1.1	14
6	Gender-related neuroanatomical differences in alcohol dependence: findings from the ENIGMA Addiction Working Group. <i>NeuroImage: Clinical</i> , 2021, 30, 102636.	1.4	17
7	Sex differences in the neuroanatomy of alcohol dependence: hippocampus and amygdala subregions in a sample of 966 people from the ENIGMA Addiction Working Group. <i>Translational Psychiatry</i> , 2021, 11, 156.	2.4	30
8	Cannabidiol regulates CB1-STAT3 signaling for neurite outgrowth, prolongs lifespan, and improves health span in <i>Caenorhabditis elegans</i> of $A\beta$ pathology models. <i>FASEB Journal</i> , 2021, 35, e21537.	0.2	18
9	Sex and dependence related neuroanatomical differences in regular cannabis users: findings from the ENIGMA Addiction Working Group. <i>Translational Psychiatry</i> , 2021, 11, 272.	2.4	14
10	Investigating the Residual Effects of Chronic Cannabis Use and Abstinence on Verbal and Visuospatial Learning. <i>Frontiers in Psychiatry</i> , 2021, 12, 663701.	1.3	1
11	Mapping cortical and subcortical asymmetries in substance dependence: Findings from the ENIGMA Addiction Working Group. <i>Addiction Biology</i> , 2021, 26, e13010.	1.4	22
12	Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration. <i>Internal Medicine Journal</i> , 2020, 50, 846-853.	0.5	11
13	Neuroanatomical alterations in people with high and low cannabis dependence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 68-75.	1.3	9
14	Subcortical surface morphometry in substance dependence: An ENIGMA addiction working group study. <i>Addiction Biology</i> , 2020, 25, e12830.	1.4	33
15	Electrophysiological correlates of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism. <i>Scientific Reports</i> , 2020, 10, 17915.	1.6	14
16	Young Adults With Higher Motives and Expectancies of Regular Cannabis Use Show Poorer Psychosocial Functioning. <i>Frontiers in Psychiatry</i> , 2020, 11, 599365.	1.3	7
17	Interrogating the Relationship Between Schizotypy, the Catechol-O-Methyltransferase (COMT) Val158Met Polymorphism, and Neuronal Oscillatory Activity. <i>Cerebral Cortex</i> , 2019, 29, 3048-3058.	1.6	8
18	A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. <i>Addiction</i> , 2019, 114, 1095-1109.	1.7	160

#	ARTICLE	IF	CITATIONS
19	Alteration to hippocampal volume and shape confined to cannabis dependence: a multi-site study. <i>Addiction Biology</i> , 2019, 24, 822-834.	1.4	30
20	Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 574-587.	2.0	32
21	A randomised controlled trial of vaporised $\delta^9$ -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 17-35.	1.8	136
22	Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 59-71.	1.8	84
23	Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109666.	2.5	34
24	The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 63.	1.3	95
25	Cortical surface morphology in long-term cannabis users: A multi-site MRI study. <i>European Neuropsychopharmacology</i> , 2019, 29, 257-265.	0.3	23
26	Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects. <i>American Journal of Psychiatry</i> , 2019, 176, 119-128.	4.0	190
27	Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 94-107.	1.5	58
28	Psychotomimetic and Cognitive Effects of Cannabis Use in the General Population. , 2018, , 129-155.		3
29	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. <i>Clinical Therapeutics</i> , 2018, 40, 1442-1447.	1.1	12
30	Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting. <i>Drugs in R and D</i> , 2018, 18, 41-44.	1.1	7
31	T189. Biomarker Prediction of Psychotherapy Outcomes in Borderline Personality Disorder: Systematic Review. <i>Biological Psychiatry</i> , 2018, 83, S201-S202.	0.7	0
32	Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 21-34.	1.5	93
33	The effects of glycine on auditory mismatch negativity in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 61-69.	1.1	46
34	The relationship between executive functions and emotion regulation in females attending therapeutic community treatment for substance use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 182, 58-66.	1.6	24
35	Peering Through the Haze of Smoked vs Vaporized Cannabis – To Vape or Not to Vape?. <i>JAMA Network Open</i> , 2018, 1, e184838.	2.8	13
36	Exploring the association of legalisation status of cannabis with problematic cannabis use and impulsivity in the USA. <i>Drugs in Context</i> , 2018, 7, 1-5.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Biomarker correlates of psychotherapy outcomes in borderline personality disorder: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 94, 166-178.	2.9	28
38	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5154-E5163.	3.3	299
39	Clinical issues in cannabis use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2495-2498.	1.1	20
40	Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. <i>Neuropsychopharmacology</i> , 2017, 42, 1447-1457.	2.8	103
41	Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users. <i>Psychopharmacology</i> , 2017, 234, 2149-2157.	1.5	25
42	Cognitive remediation improves executive functions, self-regulation and quality of life in residents of a substance use disorder therapeutic community. <i>Drug and Alcohol Dependence</i> , 2017, 178, 150-158.	1.6	39
43	Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users. <i>Psychopharmacology</i> , 2017, 234, 1985-1995.	1.5	32
44	Development and validation of a simple, rapid and sensitive LC-MS/MS method for the measurement of urinary neurotransmitters and their metabolites. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 7191-7199.	1.9	27
45	Role of orbitofrontal sulcogyral pattern on lifetime cannabis use and depressive symptoms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 392-400.	2.5	17
46	A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 72, 310-324.	2.9	126
47	Verbal Learning and Memory in Cannabis and Alcohol Users: An Event-Related Potential Investigation. <i>Frontiers in Psychology</i> , 2017, 8, 2129.	1.1	8
48	Adolescent Cannabis Use: What is the Evidence for Functional Brain Alteration?. <i>Current Pharmaceutical Design</i> , 2017, 22, 6353-6365.	0.9	38
49	Genetic imaging consortium for addiction medicine. <i>Progress in Brain Research</i> , 2016, 224, 203-223.	0.9	22
50	Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users. <i>Neural Plasticity</i> , 2016, 2016, 1-11.	1.0	6
51	The Neurobiology of Cannabis Use Disorders: A Call for Evidence. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 86.	1.0	13
52	Schizotypy and auditory mismatch negativity in a non-clinical sample of young adults. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 83-91.	0.9	11
53	The Montreal Cognitive Assessment (MoCA) is Sensitive to Head Injury and Cognitive Impairment in a Residential Alcohol and Other Drug Therapeutic Community. <i>Journal of Substance Abuse Treatment</i> , 2016, 66, 30-36.	1.5	26
54	An MRI study of white matter tract integrity in regular cannabis users: effects of cannabis use and age. <i>Psychopharmacology</i> , 2016, 233, 3627-3637.	1.5	37

#	ARTICLE	IF	CITATIONS
55	Effects of Cannabis Use on Human Behavior. <i>JAMA Psychiatry</i> , 2016, 73, 995.	6.0	18
56	Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. <i>Internal Medicine Journal</i> , 2016, 46, 1269-1275.	0.5	29
57	Hippocampal harms, protection and recovery following regular cannabis use. <i>Translational Psychiatry</i> , 2016, 6, e710-e710.	2.4	115
58	Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review. <i>Biological Psychiatry</i> , 2016, 79, 557-567.	0.7	499
59	The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. <i>Biological Psychiatry</i> , 2016, 79, e17-e31.	0.7	178
60	Gross morphological brain changes with chronic, heavy cannabis use. <i>British Journal of Psychiatry</i> , 2015, 206, 77-78.	1.7	74
61	Computerized and Virtual Reality Cognitive Training for Individuals at High Risk of Cognitive Decline: Systematic Review of the Literature. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 335-359.	0.6	182
62	A protocol for the delivery of cannabidiol (CBD) and combined CBD and $\Delta^9$ -tetrahydrocannabinol (THC) by vaporisation. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 58.	1.0	43
63	Chronic Effects of Cannabis Use on the Auditory Mismatch Negativity. <i>Biological Psychiatry</i> , 2014, 75, 449-458.	0.7	19
64	The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature. <i>Current Pharmaceutical Design</i> , 2014, 20, 2138-2167.	0.9	80
65	Chronic effects of cannabis on sensory gating. <i>International Journal of Psychophysiology</i> , 2013, 89, 381-389.	0.5	25
66	Alteration to hippocampal shape in cannabis users with and without schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 179-184.	1.1	54
67	The Impact of Regular Cannabis Use on the Human Brain. , 2013, , 711-728.		1
68	The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. <i>Schizophrenia Bulletin</i> , 2012, 38, 316-330.	2.3	219
69	Functional Connectivity in Brain Networks Underlying Cognitive Control in Chronic Cannabis Users. <i>Neuropsychopharmacology</i> , 2012, 37, 1923-1933.	2.8	98
70	Effect of long-term cannabis use on axonal fibre connectivity. <i>Brain</i> , 2012, 135, 2245-2255.	3.7	259
71	15:00 THE EFFECTS OF REGULAR LONG-TERM CANNABIS USE ON AUDITORY MISMATCH NEGATIVITY (MMN). <i>Schizophrenia Research</i> , 2012, 136, S82.	1.1	0
72	Poster #119 GENETIC MODULATION OF THE LONG-TERM EFFECTS OF CANNABIS ON BRAIN STRUCTURE, FUNCTION AND SYMPTOMATOLOGY. <i>Schizophrenia Research</i> , 2012, 136, S134.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Delayed preattentive functioning in early psychosis patients with cannabis use. <i>Psychopharmacology</i> , 2012, 222, 507-518.	1.5	20
74	Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. <i>Psychopharmacology</i> , 2012, 219, 575-586.	1.5	98
75	Cannabis and cognition: short- and long-term effects. , 2011, , 91-102.		15
76	Does cannabis cause lasting brain damage?. , 2011, , 103-113.		3
77	Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. <i>Psychopharmacology</i> , 2011, 216, 131-144.	1.5	187
78	Cerebellar white-matter changes in cannabis users with and without schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 2349-2359.	2.7	84
79	Chronic use of cannabis and poor neural efficiency in verbal memory ability. <i>Psychopharmacology</i> , 2010, 209, 319-330.	1.5	55
80	Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution. <i>Psychopharmacology</i> , 2010, 212, 613-624.	1.5	59
81	HARMS TO BODY AND SOUL – AN IDEOLOGICAL BALANCING ACT FOR PREVENTING AND REDUCING CANNABIS USE. <i>Addiction</i> , 2010, 105, 1331-1332.	1.7	6
82	Anormalidades cognitivas no uso da cannabis. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 531-540.	0.9	57
83	Structural MRI Findings in Long-Term Cannabis Users: What Do We Know?. <i>Substance Use and Misuse</i> , 2010, 45, 1787-1808.	0.7	110
84	Structural Brain Alterations in Cannabis Users: Association with Cognitive Deficits and Psychiatric Symptoms. , 2009, , 215-225.		2
85	Neurobiological and neuropsychological pathways into substance abuse and addictive behavior. , 2009, , 326-341.		3
86	Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 357-368.	1.3	80
87	Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use. <i>Archives of General Psychiatry</i> , 2008, 65, 694.	13.8	410
88	The Chronic Effects of Cannabis on Memory in Humans: A Review. <i>Current Drug Abuse Reviews</i> , 2008, 1, 81-98.	3.4	318
89	Understanding Drug Addiction: A Neuropsychological Perspective. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 957-968.	1.3	138
90	Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 30-52.	1.4	145

#	ARTICLE	IF	CITATIONS
91	Fatty acid relationships in former cannabis users with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 280-285.	2.5	6
92	Marijuana and Cannabinoid Research: Methods and Protocols. Addiction, 2006, 101, 1368-1369.	1.7	0
93	Letter to the Editor. American Journal of Psychiatry, 2006, 163, 553-553.	4.0	1
94	Cognitive and Neuropsychiatric Consequences of Endocannabinoid Signaling Dysfunction. Neuropsychopharmacology, 2006, 31, 471-472.	2.8	2
95	Acute and subacute psychomimetic effects of cannabis in humans. , 2004, , 41-53.		7
96	Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment. JAMA - Journal of the American Medical Association, 2002, 287, 1123.	3.8	658
97	Are the adverse consequences of cannabis use age-dependent?. Addiction, 2002, 97, 1083-1086.	1.7	34
98	Supportiveâ€“Expressive Psychotherapy for Cannabis Dependence. , 2001, , 225-244.		1
99	The Adverse Health and Psychological Consequences of Cannabis Dependence. , 2001, , 106-128.		3
100	Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence, 1999, 55, 105-115.	1.6	300
101	Event-related potential indices of auditory selective attention in dependent amphetamine users. Biological Psychiatry, 1999, 45, 1488-1497.	0.7	19
102	Adverse effects of cannabis. Lancet, The, 1998, 352, 1611-1616.	6.3	719
103	Long-term cannabis use and mental health. British Journal of Psychiatry, 1997, 171, 107-108.	1.7	55
104	Evoked otoacoustic emissions and auditory selective attention. Hearing Research, 1996, 98, 54-67.	0.9	35
105	Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry, 1995, 37, 731-739.	0.7	201
106	Do cognitive impairments recover following cessation of cannabis use ?. Life Sciences, 1995, 56, 2119-2126.	2.0	115
107	Biopsychosocial changes associated with cessation of cannabis use: A single case study of acute and chronic cognitive effects, withdrawal and treatment. Life Sciences, 1995, 56, 2127-2134.	2.0	23
108	The effects of between-source discriminability on attended and unattended auditory ERPs. Psychophysiology, 1993, 30, 205-220.	1.2	56

#	ARTICLE	IF	CITATIONS
109	Ecstasy (3,4-methylenedioxymethamphetamine). <i>Current Opinion in Psychiatry</i> , 1993, 6, 411-415.	3.1	20
110	Recreational MDMA use in Sydney: a profile of 'Ecstasy' users and their experiences with the drug. <i>Addiction</i> , 1992, 87, 1161-1172.	1.7	340
111	Effects of long-term cannabis use on selective attention: An event-related potential study. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 40, 683-688.	1.3	114
112	Hypothalamic modulation of thermogenesis and energy substrate utilization. <i>Brain Research Bulletin</i> , 1987, 18, 303-308.	1.4	19